Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

April 25, 2023

Study Completion Date

March 15, 2024

Conditions
Diabetic Macular OedemaRetinal Vein Occlusion with Macular Oedema
Interventions
DRUG

IBE-814 70ug

At least 10 and up to 33 participants will receive one (1) IBE-814. Route of administration: intravitreal injection.

DRUG

IBE-814 140ug

Up to 27 participants will receive two (2) IBE-814. Route of administration: intravitreal injection.

Trial Locations (21)

2000

Sydney Eye Hospital, Sydney

Sydney Retina Clinic, Sydney

2103

Eye Doctors Mona Vale, Mona Vale

2135

Strathfield Retina Clinic, Strathfield

2150

Marsden Eye Specialist, Parramatta

2220

Retina and Eye Consultants, Hurstville

2298

Newcastle Eye Hospital, Waratah

3002

Centre For Eye Research Australia, East Melbourne

3143

Armadale Eye Clinic, Malvern

Eye Surgery Associates, Malvern

4101

Queensland Eye Institute, South Brisbane

4102

Princess Alexandra Hospital, Woolloongabba

5000

Adelaide Eye and Retina Centre, Adelaide

Royal Adelaide Hospital, Adelaide

6009

Lions Eye Institute, Nedlands

8013

Southern Eye Specialists, Christchurch

Unknown

Upton Eye Specialists, Brampton

Retina Centre Of Ottawa, Ottawa

Uptown Eye Specialists, Vaughan

Grantham Hospital, Aberdeen

Prince of Wales Hospital the Chinese University of Hong Kong, Hong Kong

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Ripple Therapeutics Pty Ltd

INDUSTRY

NCT04576689 - Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy | Biotech Hunter | Biotech Hunter